Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 9/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CPT2 | P23786 | 5/20 | 0.36 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004618 | 0.91 | CPT1A (0.39) | CPT1AMAPK11MAPK14KCNH2ACKR3 | |
| SCHEMBL6004177 | 0.90 | NR1H2 (0.44) | CPT1AMAPK11MAPK14KCNH2CPT2 | |
| SCHEMBL4871021 | 0.90 | CPT1A (0.39) | CPT1AMAPK11MAPK14KCNH2ACKR3 | |
| SCHEMBL6004476 | 0.90 | ACKR3 (0.41) | CPT1AMAPK11MAPK14KCNH2CPT2 | |
| SCHEMBL4761505 | 0.85 | MAPK11 (0.52) | MAPK11MAPK14KCNH2ACKR3 | |
| SCHEMBL6004023 | 0.80 | CPT1A (0.45) | CPT1ACPT2CPT1B | |
| SCHEMBL4889031 | 0.78 | CPT1A (0.41) | CPT1AMAPK11MAPK14CPT2ACKR3 | |
| SCHEMBL4721839 | 0.78 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3 | |
| SCHEMBL4763221 | 0.76 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3 | |
| SCHEMBL4762479 | 0.76 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | CPT1A 4225/4885MAPK11 45/4885MAPK14 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.